Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab +/- Apatinib + SOX for Neoadjuvant Treatment of Gastric/GEJ Adenocarcinoma
NCT06693128Phase 2Active, not recruiting
- Sponsor
- Ruijin Hospital
- Start
- Nov 2024
- Primary completion
- May 2026
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing Camrelizumab + Apatinib + SOX with Camrelizumab + SOX (2 arms). Primary endpoint: Pathological Complete Response. Started Nov 2024; status: active, not recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06693128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06693128.